Tested Applications
| Positive WB detected in | A549 cells, Jurkat cells |
| Positive IF/ICC detected in | A549 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
26651-1-AP targets LIN37 in WB, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag24565 Product name: Recombinant human LIN37 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-93 aa of BC009071 Sequence: MFPVKVKVEKSELEMAKARNQLDAVLQCLLEKSHMDRERLDEEAGKTPSDTHNKDCSIAATGKRPSARFPHQRRKKRREMDDGLAEGGPQRSN Predict reactive species |
| Full Name | lin-37 homolog (C. elegans) |
| Observed Molecular Weight | 36 kDa |
| GenBank Accession Number | BC009071 |
| Gene Symbol | LIN37 |
| Gene ID (NCBI) | 55957 |
| RRID | AB_2880590 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q96GY3 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
LIN37, also named as Antolefinin and MSTP064, is a component of the DREAM complex (also named LINC complex). LIN37 migrates to 37 kDa for modification.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for LIN37 antibody 26651-1-AP | Download protocol |
| WB protocol for LIN37 antibody 26651-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The LIN37 Polyclonal antibody (Cat# 26651-1-AP) has 1 citation to date. It was used in a Western blot study published in the International Journal of Oncology (2024), investigating how transcription factor E2F4 promotes hepatocellular carcinoma progression via SUMOylation and interaction with LIN9. The associated research field is oncology, specifically liver cancer biology and post-translational modification mechanisms in tumor progression.
| Species | Application | Title |
|---|---|---|
Int J Oncol Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9 |



